The CYP2C8 antibody is a critical tool for studying the cytochrome P450 2C8 enzyme, a member of the CYP450 superfamily involved in metabolizing endogenous and exogenous compounds. CYP2C8. primarily expressed in the liver and intestine, plays a key role in drug metabolism (e.g., paclitaxel, repaglinide) and the processing of endogenous molecules like arachidonic acid. Genetic polymorphisms in CYP2C8 can influence drug efficacy and toxicity, driving research into its functional variability.
CYP2C8 antibodies are designed to detect and quantify the enzyme in various experimental setups, including Western blotting, immunohistochemistry, and ELISA. These antibodies, often polyclonal or monoclonal, target specific epitopes to ensure specificity, validated through techniques like knockout cell lines or enzymatic inhibition assays. Their applications span drug development, pharmacogenomics, and clinical research, particularly in assessing how genetic variants or drug interactions alter CYP2C8 activity.
In drug discovery, CYP2C8 antibodies help evaluate candidate compounds’ potential to inhibit or induce the enzyme, predicting metabolic interactions. Additionally, they aid in exploring CYP2C8’s role in diseases, such as cancer or metabolic disorders, where its expression may be dysregulated. Reliable CYP2C8 antibodies are thus vital for advancing personalized medicine and understanding complex metabolic pathways.